Strahlentherapie und Onkologie

, Volume 193, Issue 6, pp 433–443 | Cite as

Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer

A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT
  • E. Gkika
  • S. Adebahr
  • S. Kirste
  • T. Schimek-Jasch
  • R. Wiehle
  • R. Claus
  • U. Wittel
  • U. Nestle
  • D. Baltas
  • A. L. Grosu
  • T. B. Brunner
Original Article



Stereotactic body radiotherapy (SBRT) in pancreatic cancer can be limited by its proximity to organs at risk (OAR). In this analysis, we evaluated the toxicity and efficacy of two different treatment approaches in patients with locally recurrent or oligometastatic pancreatic cancer.

Materials and methods

According to the prescription method, patients were divided in two cohorts (C1 and C2). The planning target volume (PTV) was created through a 4 mm expansion of the internal target volume. In C2, a subvolume was additionally created, a simultaneous integrated protection (SIP), which is the overlap of the PTV with the planning risk volume of an OAR to which we prescribed a reduced dose.


In all, 18 patients were treated (7 with local recurrences, 9 for oligometastases, 2 for both). Twelve of 23 lesions were treated without SIP (C1) and 11 with SIP (C2). The median follow-up was 12.8 months. Median overall survival (OS) was 13.2 (95% confidence interval [CI] 9.8–14.6) months. The OS rates at 6 and 12 months were 87 and 58%, respectively. Freedom from local progression for combined cohorts at 6 and 12 months was 93 and 67% (95% CI 15–36), respectively. Local control was not statistically different between the two groups. One patient in C2 experienced grade ≥3 acute toxicities and 1 patient in C1 experienced a grade ≥3 late toxicity.


The SIP approach is a useful prescription method for abdominal SBRT with a favorable toxicity profile which does not compromise local control and overall survival despite dose sacrifices in small subvolumes.


Local progression Radiation therapy Overall survival Prognosis Toxicity 

Stereotaktische Strahlentherapie (SBRT) beim wiederkehrenden oder oligometastatischen Pankreaskarzinom

Bewertung der Toxizität bei simultan integrierter Protektion (SIP) versus konventioneller SBRT



Die stereotaktische Strahlentherapie (SBRT) ist bei Pankreaskarzinomen durch die enge Lagebeziehung der Risikoorgane (OAR) zum Zielvolumen erschwert. In dieser Analyse evaluierten wir die Toxizität und die Lokalkontrolle von zwei unterschiedlichen Therapiestrategien bei Patienten mit rezidivierendem oder oligometastatischem Pankreaskarzinom.

Material und Methoden

Die Patienten wurden anhand der Verschreibungsmethode in zwei Kohorten geteilt (C1 und C2). Das Planungszielvolumen (PTV) wurde durch eine Expansion des internen Zielvolumens (ITV) um 4 mm erzeugt. In C2 wurde zusätzlich ein Subvolumen (simultan integrierte Protektion, SIP) definiert, welches durch die Überlappung des PTV mit dem Planungsrisikovolumen (PRV) eines OAR generiert wurde, um die Grenzdosen für das jeweilige OAR einhalten zu können.


Insgesamt 18 Patienten wurden behandelt (7 Lokalrezidive, 9 Oligometastasen, 2 kombiniert). Zwölf von 23 Läsionen wurden ohne SIP (C1) und 11 mit SIP (C2) therapiert. Bei einem medianen Follow-up von 12,8 Monaten lag das mediane Überleben bei 13,2 Monaten (95 %-Konfidenzintervall [KI] 9,8–14,6). Das Gesamtüberleben nach 6 und 12 Monaten betrug je 87 % und 58 %. Die Lokalkontrolle für das Gesamtkollektiv betrug nach 6 und 12 Monaten jeweils 93 % und 67 % (95 %-KI 15–36); sie war statistisch nicht unterschiedlich zwischen den beiden Gruppen. Ein Patient in C2 entwickelte eine akute Grad-4-Toxizität und 1 Patient in C1 entwickelte eine Grad-4-Spättoxizität.


Die SIP-Verschreibungsmethode ist eine hilfreiche Strategie bei der SBRT mit einem günstigen Nebenwirkungsprofil. Trotz der Dosisreduktion in kleinen Subvolumina waren die lokale Kontrolle und das Gesamtüberleben identisch.


Lokale Progression Strahlentherapie  Gesamtüberleben Prognose Toxizität 


Compliance with ethical guidelines

Conflict of interest

E. Gkika, S. Adebahr, S. Kirste, T. Schimek-Jasch, R. Wiehle, R. Claus, U. Wittel, U. Nestle, D. Baltas, A.L. Grosu, and T.B. Brunner declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

66_2017_1099_MOESM1_ESM.docx (24 kb)
Supplementary Table 1: Treatment characteristics of the 23 lesions


  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi: 10.3322/caac.21254 CrossRefPubMedGoogle Scholar
  2. 2.
    Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA (2013) Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 31(7):886–894. doi: 10.1200/JCO.2012.44.7516 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl 5):v56–v68. doi: 10.1093/annonc/mdv295 CrossRefPubMedGoogle Scholar
  4. 4.
    Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC (2010) A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 78(5):1420–1426. doi: 10.1016/j.ijrobp.2009.09.075 CrossRefPubMedGoogle Scholar
  5. 5.
    Brunner TB, Nestle U, Grosu AL, Partridge M (2015) SBRT in pancreatic cancer: what is the therapeutic window? Radiother Oncol 114(1):109–116. doi: 10.1016/j.radonc.2014.10.015 CrossRefPubMedGoogle Scholar
  6. 6.
    Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115(3):665–672. doi: 10.1002/cncr.24059 CrossRefPubMedGoogle Scholar
  7. 7.
    Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O’Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121(7):1128–1137. doi: 10.1002/cncr.29161 CrossRefPubMedGoogle Scholar
  8. 8.
    Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63(2):320–323. doi: 10.1016/j.ijrobp.2005.07.002 CrossRefPubMedGoogle Scholar
  9. 9.
    Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58(4):1017–1021. doi: 10.1016/j.ijrobp.2003.11.004 CrossRefPubMedGoogle Scholar
  10. 10.
    Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT (2014) Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys 90(4):918–925. doi: 10.1016/j.ijrobp.2014.06.066 CrossRefPubMedGoogle Scholar
  11. 11.
    Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC (2011) Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81(1):181–188. doi: 10.1016/j.ijrobp.2010.05.006 CrossRefPubMedGoogle Scholar
  12. 12.
    Trakul N, Koong AC, Chang DT (2014) Stereotactic body radiotherapy in the treatment of pancreatic cancer. Semin Radiat Oncol 24(2):140–147. doi: 10.1016/j.semradonc.2013.11.008 CrossRefPubMedGoogle Scholar
  13. 13.
    Aitken KL, Hawkins MA (2015) Stereotactic body radiotherapy for liver metastases. Clin Oncol 27(5):307–315. doi: 10.1016/j.clon.2015.01.032 CrossRefGoogle Scholar
  14. 14.
    Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872–881. doi: 10.1007/s00066-014-0714-1 CrossRefPubMedGoogle Scholar
  15. 15.
    Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C (2010) Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 78(3):735–742. doi: 10.1016/j.ijrobp.2009.08.046 CrossRefPubMedGoogle Scholar
  16. 16.
    Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M (2011) Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 81(4):e615–622. doi: 10.1016/j.ijrobp.2011.04.045 CrossRefPubMedGoogle Scholar
  17. 17.
    Kumar R, Wild AT, Ziegler MA, Hooker TK, Dah SD, Tran PT, Kang J, Smith K, Zeng J, Pawlik TM, Tryggestad E, Ford E, Herman JM (2013) Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: A dosimetric analysis. Med Dosim 38(3):243–250. doi: 10.1016/j.meddos.2013.02.003 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Brunner TB, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D, Grosu AL (2016) Simultaneous integrated protection: a new concept for high-precision radiation therapy. Strahlenther Onkol. doi: 10.1007/s00066-016-1057-x PubMedCentralGoogle Scholar
  19. 19.
    Timmerman RD (2008) An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 18(4):215–222. doi: 10.1016/j.semradonc.2008.04.001 CrossRefPubMedGoogle Scholar
  20. 20.
    Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76(1):48–53. doi: 10.1016/j.radonc.2004.12.022 CrossRefPubMedGoogle Scholar
  21. 21.
    Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M (2010) Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 76(3 Suppl):S101–S107. doi: 10.1016/j.ijrobp.2009.05.071 CrossRefPubMedGoogle Scholar
  22. 22.
    Cattaneo GM, Passoni P, Longobardi B, Slim N, Reni M, Cereda S, di Muzio N, Calandrino R (2013) Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. Radiother Oncol 108(1):66–71. doi: 10.1016/j.radonc.2013.05.011 CrossRefPubMedGoogle Scholar
  23. 23.
    Elhammali A, Patel M, Weinberg B, Verma V, Liu J, Olsen JR, Gay HA (2015) Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas. Radiat Oncol 10:186. doi: 10.1186/s13014-015-0489-2 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K (2014) Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Am J Clin Oncol. doi: 10.1097/COC.0000000000000118
  25. 25.
    Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R (2013) Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated. Int J Radiat Oncol 86(3):516–522Google Scholar
  26. 26.
    Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G (2010) Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration. Ann Surg Oncol 17(8):2092–2101Google Scholar
  27. 27.
    Rwigema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, Bahary N, Quinn A, Burton SA (2011) Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 34(1):63–69. doi: 10.1097/COC.0b013e3181d270b4
  28. 28.
    Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, Reggiori G, Clerici E, Rimassa L, Zerbi A, Fogliata A, Cozzi L, Tomatis S, Scorsetti M (2013) SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol 8(1):148Google Scholar
  29. 29.
    Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S (2010) Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients. J Gastrointest Surg 14(10):1547–1559Google Scholar
  30. 30.
    Goyal K, Einstein D, Ibarra RA, Yao M, Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, Fabians J, Funkhouser G, Machtay M, Sanabria JR (2012) Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Pancreas. J Surg Res 174(2):319–325Google Scholar
  31. 31.
    Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AMC, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, Weiss MJ, Laheru DA, Wolfgang CL, Herman JM (2015) The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol 22(7):2352–2358Google Scholar
  32. 32.
    Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R (2015) Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 54(7):979–985Google Scholar
  33. 33.
    Comito T, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C, Navarria P, D’Agostino G, Rimassa L, Carnaghi C, Personeni N, Tronconi MC, De Rose F, Franceschini D, Ascolese AM, Fogliata A, Tomatis S, Santoro A, Zerbi A, Scorsetti M (2016) Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technol Cancer Res T. doi: 10.1177/1533034616650778

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • E. Gkika
    • 1
  • S. Adebahr
    • 1
    • 5
  • S. Kirste
    • 1
  • T. Schimek-Jasch
    • 1
  • R. Wiehle
    • 4
  • R. Claus
    • 2
  • U. Wittel
    • 3
  • U. Nestle
    • 1
    • 5
    • 6
  • D. Baltas
    • 4
    • 5
    • 6
  • A. L. Grosu
    • 1
    • 5
    • 6
  • T. B. Brunner
    • 1
    • 5
    • 6
  1. 1.Department of Radiation OncologyUniversity Medical Center FreiburgFreiburg im BreisgauGermany
  2. 2.Department of Hematology, Oncology and Stem-Cell TransplantationUniversity Medical Center FreiburgFreiburgGermany
  3. 3.Department of General and Visceral SurgeryUniversity Medical Center FreiburgFreiburgGermany
  4. 4.Division of Medical Physics, Department of Radiation OncologyUniversity Medical Center FreiburgFreiburgGermany
  5. 5.German Cancer Consortium (DKTK)Heidelberg (partner site Freiburg)Germany
  6. 6.Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations